Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Klin Padiatr ; 219(6): 372-9, 2007.
Article in German | MEDLINE | ID: mdl-18050050

ABSTRACT

Oncological diseases in children and adolescents represent a considerable burden for the children themselves and for their families. In order to position such concomitants of a life-threatening disease appropriately among the diagnostic options of psychosocial cancer care one is repeatedly confronted with the issue of giving a diagnosis from the area of reactions to burdens and adaptive disturbances (ICD 10: F: 43 ff). This touches the question of whether or not confronting a life-threatening disease in and by itself suffices to fully justify establishing one of the psychiatric diagnoses mentioned, which would imply that the intensity of the burden experienced justified the assumption of a psychiatric disturbance in the person affected. Whereas considerable effort is regularly spent on taking action and giving support and care, and reactions occasionally exceed the appropriate degree, a fair majority show no pathological processes that would justify determining a psychiatric diagnosis as a rule. Ultimately, one would arrive at a false interpretation of actually altogether adequate reactions of the patient to the burden. The ICD and DSM classification systems, however, do not provide for diagnoses other than those allocated disease status; it must therefore be considered whether it may be better in these cases to speak not of a reaction to a burden or an adaptive disturbance in the sense of the ICD 10, Section F, but rather of a sustained reaction to a burden. This opinion is increasingly gaining acceptance in pediatric oncology.


Subject(s)
Cost of Illness , Hematology , Medical Oncology , Mental Disorders/diagnosis , Neoplasms/psychology , Pediatrics , Age Factors , Child , Diagnosis, Differential , Diagnostic and Statistical Manual of Mental Disorders , Emotions , Humans , International Classification of Diseases , Mental Disorders/therapy , Practice Guidelines as Topic , Psychology , Stress, Psychological/diagnosis
2.
Phys Rev Lett ; 91(9): 091801, 2003 Aug 29.
Article in English | MEDLINE | ID: mdl-14525170

ABSTRACT

Fermilab experiment E835 has observed (-)pp annihilation production of the charmonium state chi(c0) and its subsequent decay into pi(0)pi(0). Although the resonant amplitude is an order of magnitude smaller than that of the nonresonant continuum production of pi(0)pi(0), an enhanced interference signal is evident. A partial wave expansion is used to extract physics parameters. The amplitudes J=0 and 2, of comparable strength, dominate the expansion. Both are accessed by L=1 in the entrance (-)pp channel. The product of the input and output branching fractions is determined to be B((-)pp-->chi(c0))xB(chi(c0)-->pi(0)pi(0))=(5.09+/-0.81+/-0.25)x10(-7).

3.
Hum Reprod ; 18(10): 1992-9, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14507812

ABSTRACT

In July 2002 the data of the prematurely stopped Estrogen plus Progestin study of the Women's Health Initiative (WHI) were presented in the Journal of the American Medical Association. The results of the Heart and Estrogen/Progestin Replacement Study (HERS/HERS II) were published in the same issue. The results of WHI for healthy postmenopausal women often are interpreted to be in analogy with the HERS/HERS II results for postmenopausal women with established coronary heart disease. As a result of HERS/HERS II and WHI, use of HRT in general became questionable. This is an unjustified judgement of HRT in general. This synoptic review and criticism of both studies will show the methodological weaknesses and their consequences and the reasons for limited generalizability of the study results from WHI and HERS/HERS II on normal HRT users.


Subject(s)
Coronary Disease/prevention & control , Estrogen Replacement Therapy , Biometry , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Coronary Disease/epidemiology , Coronary Disease/mortality , Data Collection , Drug Combinations , Estrogens, Conjugated (USP)/therapeutic use , Hip Fractures/epidemiology , Humans , Medroxyprogesterone Acetate/therapeutic use , Neoplasms/epidemiology , Patient Selection , Randomized Controlled Trials as Topic , Research Design , Risk
4.
Z Kinder Jugendpsychiatr Psychother ; 25(3): 168-73, 1997 Aug.
Article in German | MEDLINE | ID: mdl-9459706

ABSTRACT

Examination of a 14-year-old male who was admitted to an inpatient unit with an acute paranoid syndrome yielded serious organic findings: macroencephaly, head tilted to one side, strabismus, neurological deficits, hydroencephaly and an expressive speech disorder. The personal and family history revealed a disturbance of motor development since infancy and psychiatric illness in the immediate family. The medication and the surgical procedure selected--endoscopic third ventriculostomy--are described and the difficult differential diagnosis is discussed.


Subject(s)
Cerebral Aqueduct , Hydrocephalus/diagnosis , Neurocognitive Disorders/diagnosis , Paranoid Disorders/diagnosis , Adolescent , Cerebral Aqueduct/surgery , Diagnosis, Differential , Humans , Hydrocephalus/psychology , Hydrocephalus/surgery , Male , Neurocognitive Disorders/psychology , Neurocognitive Disorders/surgery , Paranoid Disorders/psychology , Paranoid Disorders/surgery , Ventriculostomy
9.
Maturitas ; 12(2): 127-36, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2147736

ABSTRACT

Two hormone replacement therapy regimens were tested in a double-blind clinical trial involving 49 patients. In both cases the oestrogen component was 2 mg oestradiol valerate. This was administered for 21 days and sequentially combined for 10 days with either 0.5 mg norgestrel + (Cyclo-Progynova) or 1 mg cyproterone acetate (SH D 461 A). Each treatment cycle was followed by a 7-day tablet-free period. Both regimens proved to be equally effective in alleviating climacteric complaints. However, the low-density-lipoprotein cholesterol lowering effect of SH D 461 A was found to be superior to that of Cyclo-Progynova. There were no changes in bone mineral content during the one-year treatment period with either combination.


Subject(s)
Bone Density/drug effects , Estrogen Replacement Therapy/methods , Lipoproteins/blood , Androgen Antagonists/administration & dosage , Cyproterone/administration & dosage , Cyproterone/analogs & derivatives , Cyproterone Acetate , Double-Blind Method , Drug Administration Schedule , Estradiol/administration & dosage , Estradiol/analogs & derivatives , Female , Humans , Middle Aged , Norgestrel/administration & dosage
10.
Z Geburtshilfe Perinatol ; 194(3): 126-30, 1990.
Article in German | MEDLINE | ID: mdl-2378143

ABSTRACT

The mode of delivery in 49 women with two or more previous cesarean sections was examined. In 33 cases (67%) a primary re-cesarean section was performed, in 12 of 16 patients (75%) a vaginal birth was possible. Emphasis was given to the causes leading to the latest cesarean section to the maternal and infant conditions and complications and the relevant factors from earlier cesarean sections. The results were discussed by comparison to related publications. Some fundamental considerations about the mode of delivery in cases of repeated cesarean sections were presented. The justifications for a repeated primary cesarean section based on the previous record to two or more cesarean sections alone seems to be no longer given.


Subject(s)
Cesarean Section , Obstetric Labor Complications/surgery , Trial of Labor , Asphyxia Neonatorum/surgery , Female , Humans , Infant, Newborn , Obstetric Labor, Premature/surgery , Pregnancy , Reoperation , Risk Factors
11.
Geburtshilfe Frauenheilkd ; 50(4): 319-20, 1990 Apr.
Article in German | MEDLINE | ID: mdl-2141582

ABSTRACT

We report on a 22-year old patient with an ectopic ureter ending in the vestibulum of the vagina without genital malformations. Generally, the diagnosis of this anomaly will have already been made in childhood, because of enuresis uretica and therapy-resistant vaginal discharge. The methods of diagnosis leading to this anomaly, which is rare at that age, and the therapeutic requirements are shown.


Subject(s)
Abdominal Pain/etiology , Leukorrhea/etiology , Ureter/abnormalities , Vagina/abnormalities , Adult , Diagnosis, Differential , Enuresis/etiology , Female , Humans , Laparoscopy , Pyelonephritis/etiology
12.
Zentralbl Gynakol ; 112(7): 411-9, 1990.
Article in German | MEDLINE | ID: mdl-2368527

ABSTRACT

Breast-conserving therapy in mammary carcinoma is an alternative to the more radical forms of therapy when the tumors are small. The cosmetic results obtained are not always satisfactory. Correction of deformities of this kind in breasts which have been subjected to post-operative radiation is difficult and dangerous. Consequently, reconstruction of the mammary gland should be included in the primary operation. The technical possibilities for doing so are listed. It seems to be justifiable from an oncological point of view.


Subject(s)
Breast Neoplasms/surgery , Breast/surgery , Mastectomy, Segmental/methods , Surgery, Plastic/methods , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Surgical Flaps
14.
Eur J Cancer ; 26(5): 608-10, 1990.
Article in English | MEDLINE | ID: mdl-2144750

ABSTRACT

Competition studies with progesterone and estradiol receptors of human myometrial tissue as well as of mammary cancer tissue showed that gestodene bound with high affinity to the progesterone receptor, as did other synthetic and natural progestogens. However, gestodene did not bind to the estradiol receptor. The relative binding affinities of all tested synthetic and natural ligands showed no organ-specific differences and no differences between neoplastically transformed and normal tissues.


Subject(s)
Breast Neoplasms/metabolism , Norpregnenes/metabolism , Progesterone Congeners/metabolism , Receptors, Estrogen/metabolism , Binding, Competitive , Female , Humans , In Vitro Techniques , Myometrium/metabolism , Promegestone/metabolism , Receptors, Progesterone/metabolism
15.
Contraception ; 40(3): 325-41, 1989 Sep.
Article in English | MEDLINE | ID: mdl-2548807

ABSTRACT

Gestodene, 17 alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one, is a new orally active progestational agent, which is available for clinical use in oral contraceptives. The aim of the present study is to make a broad characterization of gestodene at the receptor level and to discuss the results in comparison to those of established progestogens. Kinetic studies of 3H-gestodene uptake show a rapid increase in the amount of specific binding during the first three hours. After saturation, the amount of specifically bound 3H-gestodene remained almost constant up to 24 hours at 4 degrees C. The dissociation of 3H-gestodene from the cytoplasmic myometrial progestone receptor, measured by displacement of labeled steroid with dextran-coated charcoal treatment at 4 degrees C at various times, showed a biphasic or two-component first order dissociation curve. As anticipated, sucrose gradient centrifugation analysis of the 3H-gestodene-labeled cytosol of human myometrial tissue showed that the gestodene binding components sedimented in the 4S and 8S region. A 200-fold molar excess of nonradioactive gestodene reduced only the 8S binding of 3H-gestodene. 4S binding of 3H-gestodene was not reduced, which indicate the existence of a second high capacity binding component. In biological test systems, such as the Clauberg test or Kaufmann test, gestodene has proved to be a very effective progestogen. Among nortestosterone derivatives it is one of the most potent and resembles progesterone biologically in its progestogenic effects. This biologically identical gestagenic activity of gestodene and progesterone is reflected by a very similar behavior in vitro in terms of binding to progesterone receptors of human uterus cytosol. Furthermore, competitive studies indicated that gestodene like other synthetic progestagens also displays some affinity for androgen and glucocorticoid receptors but no measurable affinity for the estrogen receptor. Remarkable is the high binding affinity of gestodene to the binding sites of the mineralocorticoid receptor of rat kidney with a RBA value of 350% compared to aldosterone.


Subject(s)
Blood Proteins/metabolism , Norpregnenes/metabolism , Progestins/metabolism , Receptors, Progesterone/metabolism , Receptors, Steroid/metabolism , Animals , Binding, Competitive , Contraceptives, Oral, Hormonal/metabolism , Cytosol/metabolism , Female , Humans , Kinetics , Mineralocorticoids/metabolism , Protein Binding , Rats , Rats, Inbred Strains , Receptors, Mineralocorticoid , Uterus/metabolism
16.
Contraception ; 40(2): 213-32, 1989 Aug.
Article in English | MEDLINE | ID: mdl-2758842

ABSTRACT

Recently, in the laboratories of Schering in Germany a competitive progesterone antagonist, ZK 98,734, was synthetized, which is characterized by a similar antigestagenic activity as RU 38,486, synthezised by Roussel-Uclaf in France, as assessed by inhibition of nidation tests in rats and guinea pigs. However, this compound has a substantially lower antiglucocorticoid activity measured in cell culture systems than RU 38,486. The purpose of this study was to present a comparison of biochemical and physical properties of the complexes formed by the human uterine progesterone receptor with 3H-ZK 98,734 on one hand and with other well-established progestins on the other hand. ZK 98,734 competed in the same order of magnitude as progesterone or RU 38,486 for the 3H-R5020 binding site of progestin receptor, whereas R5020, Org 2058 or progesterone were unable to compete against 3H-ZK 98,734. This apparent contradiction could be explained by means of FPLC-chromatography and sucrose density centrifugation technique. FPLC-chromatography with an anion exchange column (Mono Q, Pharmacia, Uppsala, Sweden) showed that 3H-ZK 98,734 forms at least two stable complexes with uterine cytosol, on one hand with serum albumin, which presents almost 90% of bound radioactivity, and on the other hand with the two native progestin receptor forms, corresponding to 4S and 8S receptor forms in sucrose density gradient analysis. Competition experiments in liver cytosol of adrenalectomized rats with increasing concentrations of unlabeled ligands other than dexamethasone showed that ZK 98,734, RU 38,486 and cortisol displaced 3H-dexamethasone efficiently from the binding sites in the cytosol. Furthermore, results concerning the specificity of 3H-cortisol binding to serum proteins in diluted pregnant serum demonstrated that ZK 98,734 did not compete with 3H-cortisol for serum binding.


Subject(s)
Estrenes/metabolism , Progestins/antagonists & inhibitors , Receptors, Progesterone/metabolism , Animals , Binding, Competitive , Cellulose/analogs & derivatives , Centrifugation, Density Gradient , Chromatography, High Pressure Liquid , DNA/analogs & derivatives , DNA-Binding Proteins/analysis , Female , Humans , In Vitro Techniques , Liver/metabolism , Progestins/metabolism , Protein Binding , Rats , Receptors, Glucocorticoid/metabolism , Transcortin/metabolism , Uterus/metabolism
18.
Wien Med Wochenschr ; 138(21): 552-6, 1988 Nov 15.
Article in German | MEDLINE | ID: mdl-3144097

ABSTRACT

The current therapy study with 50 patients showed that a reversible down regulation of the ovaries is possible. Particularly in cases with severe endometriosis a rapid release of pain can usually be achieved. Further development of the disease could be prevented and in two third of the cases even a partial reduction of tumor size. Within 12 weeks after the therapy the cycle is normally stabilized. But in about 70% of the patients the typical complaints of endometriosis were recurrent. The advantage of this treatment is the high acceptance of the patients in comparison to steroid medication. In long term administration it is mandatory to control bone and lipid metabolism.


Subject(s)
Buserelin/therapeutic use , Endometriosis/drug therapy , Genital Neoplasms, Female/drug therapy , Adult , Dysmenorrhea/drug therapy , Endometriosis/pathology , Female , Follow-Up Studies , Genital Neoplasms, Female/pathology , Genitalia, Female/pathology , Humans , Luteinizing Hormone/blood , Progesterone/blood
20.
J Perinat Med ; 16(5-6): 467-76, 1988.
Article in English | MEDLINE | ID: mdl-3241293

ABSTRACT

The paper reports on nine twin pregnancies in the years 1982-1987 with the intrauterine death of a single fetus. The incidence of 0.10% is consistent with that reported in other comparable studies. Evaluation of the causes of death shows a preponderance of asphyxia. A fetofetal transfusion syndrome occurred in 4 cases. Eight of the pregnancies were terminated by caesarean section. One of the surviving children died in the neonatal period. The course of the neonatal period in the other babies was determined mainly by the state of maturity. No increased maternal morbidity was observed. On the basis of this and other experience described in the literature, some general guidelines are proposed for the management of the further pregnancy and delivery in such high-risk cases.


Subject(s)
Diseases in Twins/therapy , Fetal Death , Pregnancy Complications/therapy , Pregnancy, Multiple , Prenatal Care , Adult , Delivery, Obstetric , Female , Fetal Monitoring , Gestational Age , Humans , Infant, Newborn , Male , Pregnancy , Pregnancy Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...